Nothing Special   »   [go: up one dir, main page]

AR071598A1 - Uso de epotilona dpara el tratamiento de enfermedades asociadas a tau incluso enfermedad de alzheimer - Google Patents

Uso de epotilona dpara el tratamiento de enfermedades asociadas a tau incluso enfermedad de alzheimer

Info

Publication number
AR071598A1
AR071598A1 ARP090101472A ARP090101472A AR071598A1 AR 071598 A1 AR071598 A1 AR 071598A1 AR P090101472 A ARP090101472 A AR P090101472A AR P090101472 A ARP090101472 A AR P090101472A AR 071598 A1 AR071598 A1 AR 071598A1
Authority
AR
Argentina
Prior art keywords
disease
dementia
parkinsonism
treatment
including alzheimer
Prior art date
Application number
ARP090101472A
Other languages
English (en)
Inventor
Charles Albright
Francis Y Lee
Donna Marie Barten
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40887113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR071598(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR071598A1 publication Critical patent/AR071598A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Métodos de tratamiento de tauopatías mediante el uso de epotilona D que presenta buena penetracion cerebral, vida media larga y alta retencion selectiva en cerebro, y proporciona terapias efectivas para el tratamiento de tauopatías, incluso la enfermedad de Alzheimer. Reivindicacion 3: El uso de acuerdo con la reivindicacion 1, en donde la enfermedad asociada a Tau se selecciona de demencia frontotemporal, incluso el subtipo de demencia frontotemporal y parkinsonismo ligado al cromosoma 17 (FTDP-17), parálisis supranuclear progresiva, degeneracion corticobasal, enfermedad de Pick y enfermedad argirofílica granulosa, enfermedad de Parkinson, síndrome de Down, parkinsonismo post-encefálico, distrofia miotonica, enfermedad de Niemann-Pick C, demencia pugilística, enfermedad de Blint, una enfermedad prionica, esclerosis lateral amiotrofica, complejo de parkinsonismo-demencia de Guam, esclerosis multiple, glaucoma, retinopatía diabética y dano cerebral traumático.
ARP090101472A 2008-04-24 2009-04-24 Uso de epotilona dpara el tratamiento de enfermedades asociadas a tau incluso enfermedad de alzheimer AR071598A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4772908P 2008-04-24 2008-04-24

Publications (1)

Publication Number Publication Date
AR071598A1 true AR071598A1 (es) 2010-06-30

Family

ID=40887113

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101472A AR071598A1 (es) 2008-04-24 2009-04-24 Uso de epotilona dpara el tratamiento de enfermedades asociadas a tau incluso enfermedad de alzheimer

Country Status (26)

Country Link
US (3) US20090270465A1 (es)
EP (1) EP2276485B1 (es)
JP (1) JP5548675B2 (es)
KR (1) KR20100137576A (es)
CN (3) CN102076339A (es)
AR (1) AR071598A1 (es)
AU (1) AU2009240538B2 (es)
BR (1) BRPI0911482A2 (es)
CA (1) CA2722371C (es)
CL (1) CL2009000990A1 (es)
CY (1) CY1115617T1 (es)
DK (1) DK2276485T3 (es)
EA (1) EA021758B1 (es)
ES (1) ES2501565T3 (es)
HK (1) HK1153152A1 (es)
HR (1) HRP20140783T1 (es)
HU (1) HUE024506T2 (es)
IL (1) IL208926A0 (es)
MX (1) MX2010011209A (es)
NZ (1) NZ588555A (es)
PL (1) PL2276485T3 (es)
PT (1) PT2276485E (es)
SI (1) SI2276485T1 (es)
TW (1) TWI472329B (es)
WO (1) WO2009132253A1 (es)
ZA (1) ZA201007460B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3327016T1 (sl) 2006-04-07 2021-09-30 Vertex Pharmaceuticals Incorporated Priprava modulatorjev prenašalcev z ATP-vezavno kaseto
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
EP2155197A4 (en) * 2007-03-09 2011-10-12 Link Medicine Corp TREATMENT OF LYSOSOMAL STORAGE DISEASES
WO2009151683A2 (en) 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
SI2276485T1 (sl) 2008-04-24 2014-10-30 Bristol-Myers Squibb Company Uporaba epotilona D pri zdravljenju Tau- povezanih bolezni, vključno z Alzheimerjevo boleznijo
EP2358370A2 (en) * 2008-11-13 2011-08-24 Link Medicine Corporation Treatment of proteinopathies using a farnesyl transferase inhibitor
MX2011005096A (es) 2008-11-13 2011-11-18 Link Medicine Corp Derivados de azaquinolinona y usos de los mismos.
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CA3108488A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) * 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
EP2811980A4 (en) * 2012-01-31 2015-12-23 Cerulean Pharma Inc POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS AND METHODS OF USE THEREOF
SG11201408626YA (en) 2012-07-03 2015-03-30 Univ Washington Antibodies to tau
WO2014014841A1 (en) 2012-07-16 2014-01-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
IL303422A (en) 2014-04-15 2023-08-01 Vertex Pharma Pharmaceutical preparations for the treatment of diseases related to cystic fibrosis transmembrane conductance regulator modulators
TW202136296A (zh) 2014-06-27 2021-10-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
JP6321521B2 (ja) * 2014-11-04 2018-05-09 Well Stone 有限会社 タウ蛋白産生促進剤、タウ蛋白の欠乏に起因する疾患の治療薬・予防薬および治療用・予防用食品組成物
CA3028035A1 (en) 2016-07-14 2018-01-18 Bioarctic Ab Brain delivery protein
CA3184960A1 (en) * 2020-09-02 2022-03-10 Li Tang Solid oral formulation of utidelone
CN113005086B (zh) * 2021-02-01 2022-10-28 中国科学院遗传与发育生物学研究所 埃博霉素D和Apol8在调控神经干细胞定向神经元分化中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5580898A (en) * 1994-05-24 1996-12-03 The Trustees Of The University Of Pennsylvania Method of stabilizing microtubules
PT1186606E (pt) 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf Derivados do epotilone sua preparacao e utilizacao
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
KR100574454B1 (ko) * 1997-12-04 2006-04-27 브리스톨-마이어즈 스퀴브 컴페니 옥시라닐 에포틸론을 환원시켜 올레핀계 에포틸론을 제조하는 방법
US6320045B1 (en) * 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
WO1999043653A1 (en) 1998-02-25 1999-09-02 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
IL141074A0 (en) 1998-07-27 2002-02-10 Brosow Joergen Security paper, method and device for checking the authenticity of documents recorded thereon
KR100716272B1 (ko) 1998-11-20 2007-05-09 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
CN1205208C (zh) * 1999-02-22 2005-06-08 生物技术研究股份有限公司 C-21修饰的环氧噻酮类化合物
US6998256B2 (en) 2000-04-28 2006-02-14 Kosan Biosciences, Inc. Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
US20020137152A1 (en) 2000-07-25 2002-09-26 Daniel Santi Fermentation process for epothilones
JP3604337B2 (ja) * 2000-10-03 2004-12-22 古河電気工業株式会社 絶縁電線の製造方法
WO2002032844A2 (de) 2000-10-16 2002-04-25 Morphochem Ag Epothilone-synthesebausteine iii und iv: unsymmetrisch substituierte acyloine und acyloinderivate, verfahren zu deren herstellung sowie verfahren zur herstellung von epothilon b, d und epothilonderivaten
TW476749B (en) * 2000-11-17 2002-02-21 Nat Science Council Process for preparing 2,6-dimethylphenol
FR2817117B1 (fr) 2000-11-24 2005-11-04 Commissariat Energie Atomique Mammiferes non-humains transgeniques ou recombinants et leurs applications dans le criblage de medicaments utiles dans les desordres psychoactifs
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
WO2002062293A2 (en) * 2001-02-02 2002-08-15 The Regents Of The University Of California Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
MXPA03010909A (es) * 2001-06-01 2004-02-17 Bristol Myers Squibb Co Derivados de epotilona.
ATE380861T1 (de) 2002-02-25 2007-12-15 Kosan Biosciences Inc Modulation der verteilung artverwandter sekundärer metaboliten
US7082674B2 (en) * 2002-02-27 2006-08-01 Sumitomo Heavy Industries, Ltd. Method for winding a single coil of a coil unit for a linear motor
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
DE60330651D1 (en) * 2002-03-12 2010-02-04 Bristol Myers Squibb Co C3-cyanoepothilonderivate
DK1521752T3 (da) 2002-07-15 2009-06-22 Helmholtz Infektionsforschung Makrocykliske forbindelser til behandling af cancer
AU2003260723A1 (en) 2002-08-17 2004-03-03 The Queens Universlty Of Belfast Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer
RU2368661C2 (ru) 2002-09-23 2009-09-27 Бристол-Маерс Сквибб Компани Способы получения, выделения и очистки эпотилона b и рентгеноструктурные кристаллические структуры эпотилона в
WO2004087673A2 (en) * 2003-03-28 2004-10-14 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof
US6954131B2 (en) * 2003-04-02 2005-10-11 Illinois Tool Works Inc. Electrical reactor assembly having center taps
MXPA06003835A (es) * 2003-10-09 2006-06-14 Kosan Biosciences Inc Formulaciones terapeuticas.
EP1559447A1 (en) * 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
WO2006009178A1 (ja) 2004-07-20 2006-01-26 Toshinori Kato 生体機能診断装置、生体機能診断方法、生体用プローブ、生体用プローブ装着具、生体用プローブ支持具及び生体用プローブ装着支援具
WO2006033913A2 (en) * 2004-09-16 2006-03-30 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amides) for treament of hyperplasia
TW200817348A (en) * 2006-08-21 2008-04-16 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
EP2061451A2 (en) * 2006-08-21 2009-05-27 Synta Pharmaceuticals Corporation Bis(thiohydrazide amides) for treating melanoma
BRPI0716435A2 (pt) * 2006-08-21 2014-03-04 Synta Pharmaceuticals Corp Compostos para o tratamento de doenças proliferativas
SI2276485T1 (sl) 2008-04-24 2014-10-30 Bristol-Myers Squibb Company Uporaba epotilona D pri zdravljenju Tau- povezanih bolezni, vključno z Alzheimerjevo boleznijo

Also Published As

Publication number Publication date
KR20100137576A (ko) 2010-12-30
SI2276485T1 (sl) 2014-10-30
ZA201007460B (en) 2012-03-28
PL2276485T3 (pl) 2014-12-31
WO2009132253A1 (en) 2009-10-29
DK2276485T3 (da) 2014-10-13
HRP20140783T1 (hr) 2014-09-12
CL2009000990A1 (es) 2010-10-15
PT2276485E (pt) 2014-10-20
JP5548675B2 (ja) 2014-07-16
CN104116736A (zh) 2014-10-29
EP2276485A1 (en) 2011-01-26
NZ588555A (en) 2012-06-29
CA2722371A1 (en) 2009-10-29
EA201001695A1 (ru) 2011-08-30
US20140135367A1 (en) 2014-05-15
ES2501565T3 (es) 2014-10-02
IL208926A0 (en) 2011-01-31
TW200948360A (en) 2009-12-01
AU2009240538B2 (en) 2014-08-07
JP2011522782A (ja) 2011-08-04
US20090270465A1 (en) 2009-10-29
EP2276485B1 (en) 2014-07-16
US8673949B2 (en) 2014-03-18
CY1115617T1 (el) 2017-01-04
EA021758B1 (ru) 2015-08-31
CA2722371C (en) 2016-06-21
BRPI0911482A2 (pt) 2017-08-29
US20110230528A1 (en) 2011-09-22
CN104666297A (zh) 2015-06-03
AU2009240538A1 (en) 2009-10-29
HK1153152A1 (en) 2012-03-23
TWI472329B (zh) 2015-02-11
CN102076339A (zh) 2011-05-25
MX2010011209A (es) 2010-11-12
HUE024506T2 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
AR071598A1 (es) Uso de epotilona dpara el tratamiento de enfermedades asociadas a tau incluso enfermedad de alzheimer
CL2009000380A1 (es) Compuestos derivados de heterociclos, moduladores de beta-amiloide; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la enfermedad de alzheimer, angioplastia cerebral amiloide, demencia multiinfarto, sindrome de down, entre otras.
MX2020012868A (es) Metodos y composiciones para trastornos del sue?o y otros trastornos.
BR112014027584A2 (pt) compostos e composições para inibir a atividade de abl1, abl2 e bcr-abl1
BR112012018386A8 (pt) "inibidores isoindolinona de fosfatidilinositol 3-quinase"
CL2011001265A1 (es) Compuestos derivados de 2h-pirazolo[3,4-d]-pirimidin 4,6(5h,7h)- diona, inhibidores de fosfodiesterasa 1 (pde1); composicion farmaceutica; util en el tratamiento de enfermedades que involucran trastornos relacionados con dopamina d1, tales como parkinson, depresion, narcolepsia, esquizofrenia, entre otros.
BR112014026383A2 (pt) derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl1
TN2009000381A1 (en) C5 antigens and uses thereof
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
CL2010001159A1 (es) Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros.
NZ591057A (en) Complement antagonists and uses thereof
CL2007001731A1 (es) Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
UA109459C2 (xx) ПОХІДНІ 5,6-ДИГІДРОІМІДАЗО[1,2-a]ПІРАЗИН-8-ІЛАМІНУ, ПРИДАТНІ ЯК ІНГІБІТОРИ БЕТА-СЕКРЕТАЗИ (BACE)
CL2007001732A1 (es) Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
CL2014000246A1 (es) Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros
CL2008002809A1 (es) Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros.
BR112014031531A2 (pt) composto, composição farmacêutica, métodos de tratamento ou prevenção de uma patologia relacionada com ab, e, de tratamento ou prevenção de mal de alzheimer em um paciente em necessidade do mesmo
AU2011305525A8 (en) Modulators of the GPR119 receptor and the treatment of disorders related thereto
MA45504B1 (fr) Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
ATE507214T1 (de) Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität
MX2015007611A (es) Parche para tratamiento de enfermades del parpado que contiene clobetasol.
MX354127B (es) Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central.
MX340564B (es) Isoformas de neurregulina solubles activas modificadas post-traduccionalmente.
IL179831A0 (en) Human autism susceptibility gene encoding prkcb1 and uses thereof
IL185868A0 (en) Human autism susceptibility gene encoding a transmembrane protein and uses thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure